• Understanding GA
    • Signs and Symptoms
    • Risk Factors
    • The Complement System
  • GA Burden
    • Impact of GA
    • Patient Perspectives
  • Recognize and Refer
    • Importance of Recognition
    • Imaging for GA
      • OCT B-scan
      • OCT en face and NIR
      • FAF
      • CFP
    • Patient Case Studies
  • Resources
    • For Optometrists
    • For Patients

Sitemap

  • Understanding GA
    • Signs and Symptoms
    • Risk Factors
    • The Complement System
  • GA Burden
    • Impact of GA
    • Patient Perspectives
  • Recognize and Refer
    • Importance of Recognition
    • Imaging for GA
      • OCT B-scan
      • OCT en face and NIR
      • FAF
      • CFP
    • Patient Case Studies
  • Resources
    • For Optometrists
    • For Patients
  • Email Sign Up
Contact Us
|
Privacy Policy
|
Terms and Conditions
|
Sitemap

The APELLIS® name and logo is a registered trademark of Apellis Pharmaceuticals, Inc. Other trademarks referenced herein are the property of their respective owners. © 2023 Apellis Pharmaceuticals, Inc. 4/24 US-GA-2300090 v3.0

This site is intended for US eye care professionals only.

Year 4

BCVA: 20/25
Choroidal hypertransmission defect indicative of atrophy.

Thank you for signing up!

You should receive a welcome email in your inbox shortly.

You are now leaving RecognizeAndReferGA.com

This link will take you to another Apellis Pharmaceuticals, Inc. website.

Are you a US eye care professional?